Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Genuine Parts Company (GPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Genuine Parts Company — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $224 (market cap $29.60B), while Genuine Parts Company trades at $135.22 (market cap $18.62B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Genuine Parts Company pays a 3.15% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | GPC | |
|---|---|---|
Market Cap | $29.60B | $18.62B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $149.26 |
52-Week Low | $205.48 | $92.47 |
Enterprise Value | $27.56B | $24.72B |
Dividend Yield | — | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $223.43, up 2.97% in 24 hours, with a bearish technical signal despite recent gains. The stock shows strong profitability with a 79.65% gross margin and 96.55% ROE, but valuation ratios like P/E of 38.54 are elevated. Recent Q2 2026 earnings missed estimates, and multiple law firms are investigating potential securities fraud, adding uncertainty.
Outlook is mixed: analyst consensus is bullish with a $370.07 price target, but risks include ongoing fraud probes and earnings volatility. Revenue growth is robust, projected to reach $4.8B in 2026, yet investors face headwinds from legal issues and technical bearishness.
GPC trades at $133.89, down 0.48% today, with a bullish technical outlook from moving averages but overbought RSI signals. Recent Q2 2026 earnings beat expectations with EPS of $2.15 versus $2.08 expected, driven by 6% sales growth. The company maintains a dividend payout, with a $1.06 dividend declared for H1 2026. Valuation shows a high P/E of 540.36 but a reasonable P/S of 0.75, while net income margins remain thin at 0.13% for 2025.
Outlook is mixed: analyst consensus targets $148.67 with 43% buy ratings, but profitability challenges and rising debt-to-asset ratios pose risks. The stock's proximity to its 52-week high suggests limited near-term upside, requiring careful monitoring of margin improvements and industrial segment performance to justify further gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Genuine Parts Company
Genuine Parts sells automotive parts (about two thirds of net sales) and industrial components. The company sells vehicle parts to commercial and retail customers through roughly 9,700 stores worldwide, most of which are independently owned. Its industrial unit, primarily operating under the Motion Industries banner in the United States, supplies bearings, power transmission, industrial automation, hydraulic, and pneumatic components to maintenance, repair, and OEM clients.
Read more on GPC →
